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Abstract
Rationale: Pure ground glass opacities (GGO), identified incidentally or on lung cancer
screening, may indicate pre-invasive subtypes of lung adenocarcinoma. These neoplasms
typically demonstrate indolent patterns of growth, and Fleischner Society guidelines recommend
up to five years of serial imaging. Our aim was to determine the frequency of diagnosed lung
adenocarcinoma arising from GGO detected beyond 5 years of CT surveillance.
Methods: We reviewed all pathologic diagnoses of lung adenocarcinoma (n=442) between 2016
and 2018 of a tertiary academic hospital and National Cancer Institute-designated cancer center
to identify all cancers that arose from ground glass opacities detected on CT scan. Data extracted
from the EMR included demographics, imaging characteristics and clinical outcomes.
Results: Of the 442 cases of lung adenocarcinoma, 32 (7%) were found that arose from pure
GGOs and were ultimately diagnosed as cancer. Among the subgroup of GGOs, 74% (n=24)
were diagnosed within the first five years of surveillance, but up to 26% (n=8) required between
five and twelve years of serial follow up prior to definitive diagnosis. In order to detect 95% of
cancers, GGOs would need to be followed for 7.9 to 12.7 years based upon a Kaplan-Meier
estimate for time to diagnosis (p =0 .05). No patients who had lung adenocarcinoma arising from
GGOs died (0/31) within a follow-up time of one to three years.
Conclusion: These data suggest that a greater number of lung adenocarcinomas would be
detected upon routine follow up of GGOs that extended beyond the current recommendation of
five years. Furthermore, the overall survival of the cohort was 100% (with one to three years of
follow-up) consistent with existing data that these cancers are indolent. It is unknown whether a

higher detection rate would impact overall survival. More extended observation time and a
prospective approach are required for confirmation of our findings.

